Class | Brand | Generic | Indications | Dose Forms | Route | Adult Dosing | Ped. Dosing | MOA |
Antidepressant; SSRI | Zoloft | Sertraline | Major depressive disorder; OCD; panic disorder; PTSD; premenstrual dysphoric disorder; social phobia | Oral Soln: 20mg/ml;
Oral Tablet:
25, 50, 100mg | Oral | Varies | 6YO+
OCD treatment
6-12YO: 25mg/day; 13-17YO: 50mg/day… Treatments in AM or PM, may increase at 1 week intervals to max of 200mg/day | SSRI
Enhance serotonin activity in the CNS |
Antidepressant; SNRI | Cymbalta | Duloxetine | Diabetic peripheral neuropathy (pain), fibromyalgia, anxiety disorder, major depressive disorder, musculoskeletal pain (chronic) | Oral Capsule (Delayed Release):
20, 30, 60mg | Oral | Varies
Max: 120mg/day | 7YO+
Max: 120mg/day | SNRI
Serotonin, NE reuptake inhibitor |
Antidepressant; SNRI | Effexor; Effexor XR | Venlafaxine | Generalized anxiety disorder, major depressive disorder, panic disorder, social phobia | ER Capsule:
37.5, 75, 150mg;
Oral Tablet:
25, 37.5, 50, 75, 100mg;
ER Tablet:
37.5, 75, 150, 225mg | Oral | 37.5-75mg/day, may increase by 75mg per day every 4 days
Max ER: 225mg/day
Max IR: 375mg/day | N/A | SNRI
It inhibits neuronal Serotonin, NE, and DA reuptake. |
Antidepressant; Triazolopyridine | Desyrel | Trazodone | Depression | IR Tablet:
50, 100, 150, 300mg;
ER Tablet:
150, 300mg | Oral | IR Tablet: 150mg QD, may increase by 50mg/day ever 3 to 4 days
(max of 600mg/day)
ER Tablet: 150mg QPM or HS, may increase by 75mg/day every 3 days (max 375mg/day) | N/A | Selectively inhibits neuronal reuptake of serotonin and acts as an antagonist at 5-HT-2A/2C serotonin receptors; also has α-1 antagonistic property which is associated with postural hypotension |
Tricyclic Antidepressant | Elavil | Amitriptyline | Depression | Oral Tablet:
10, 25, 50, 75, 100, 150mg | Oral | 50-100mg HS (max 150mg/day for outpatients and 300mg/day for inpatients) | 12YO+:
10mg TID and 20mg HS | Promotes neuronal activity by blocking the membrane pump mechanism which is responsible for the absorption of serotonin and NE in serotonergic & adrenergic neurons |
Antimigraine; Serotonin Receptor Agonist (5-HT1) | Imitrex | Sumatriptan | Migraine,
Cluster HA | Oral Tablet:
25, 50, 100mg; SubQ Soln: 4mg/0.5ml, 6mg/0.5ml
Nasal Soln:
5mg/act
20mg/act | Oral, SubQ, Nasal | Tablets:
25-100mg initially, may repeat after 2 hrs if needed
(max 200mg/day);
SubQ:
6mg, repeat in 1 hr if needed
(max of 6mg/dose and 12mg/24hrs)
Nasal:
5-20mg, may repeat after 2 hrs.
(max 0f 40mg/24hrs) | N/A | Selective 5-HT1 receptor agonist, stimulating vasoconstriction in the basilar artery & blood vessels of the Dura mater |
CNS Agent;
N-Methyl-D-Aspartate Receptor Antagonist (NMDA antagonist) | Namenda,
Namenda XR | Memantine | Alzheimer’s Disease (moderate to severe) | Oral Soln:
2mg/ml;
Oral Tablet:
5 or 10mg;
ER Oral Capsule: 7, 14, 21, 28mg
Namenda Titration pack:
49tabs (28x5mg, 21x10mg)
Namenda XR Titration Pack:
28caps (7x7mg, 7x14mg, 7x21mg, 7x28mg) | Oral | IR Tablets:
initial = 5mg/day, may increase at minimum of 1 week increments (5mg BID, then 10+5mg, then 10mg BID); target dose is 20mg QD (or 10mg BID)
ER Capsules: initial = 7mg/day, may increase like IR; target & max dose is 28mg/day | N/A | Low to moderate affinity noncompetitive N-methyl-D-aspartate (NMDA) receptor antagonist |
CNS Agent;
NE Reuptake Inhibitor | Strattera | Atomoxetine | ADHD | Oral Capsule:
10, 18, 25, 40, 60, 80, 100mg | Oral | 40mg/day; increase after a minimum of 3 days to target dose of approx. 80mg/day (max dose is 100mg/day) | Varies
6YO+ | Selective NE reuptake inhibitor |
Anticonvulsant; CNS Agent; Fructopyranose Sulfamate | Topamax | Topiramate | Lennox-Gastaut syndrome (adjunct); migraine (prophylaxis); partial seizure; tonic-clonic seizure | Oral Capsule:
15 or 25 mg;
Oral Tablet:
25, 50, 100, 200mg;
ER Capsule:
25, 50, 100, 150, 200mg | Oral | Varies | Varies | Exact is unknown, but there is blockage of voltage-gated Na+ channels, augmentation of GABA-A activity, AMPA/kainite antagonism of glutamate receptor, and inhibition of carbonic anhydrase enzyme (isozymes 2 & 4) |
Aminoketone; Antidepressant; Smoking Cessation Agent | Wellbutrin (SR, XL); Zyban | Bupropion | Depression;
major depressive disorder;
smoking cessation assistance | Oral Tablet:
75 or 100mg;
ER 12hr Tablet: 100, 150, 200mg;
ER 24hr Tablet: 150 or 300mg | Oral | Varies | N/A | Weakly inhibits the neuronal uptake of dopamine and NE, but doesn’t inhibit monoamine oxidase or the reuptake of serotonin |
Smoking Cessation Agent | Chantix | Varenicline | Smoking cessation assistance | Oral Tablet:
0.5mg, 1mg | Oral | Days 1-3:
0.5mg qd
Days 4-7:
0.5mg bid
Days 8-end:
1mg bid | N/A | Produces agonist activity at a subtype of nicotinic receptor, while preventing nicotine binding to
alpha-4-beta-2 receptors |
Immunological Agent; Monoclonal Antibody | Avastin | Bevacizumab | Cervical cancer, Glioblastoma multiforme of brain; metastatic colorectal cancer; metastatic renal cell carcinoma; nonsquamous non-small cell lung cancer, ovarian cancer | IV Soln:
400mg/16ml
100mg/4ml
(25mg/ml) | IV | Varies | N/A | Recombinant humanized monoclonal IgG1 antibody, binds to vascular endothelial growth factor (VEGF) & inhibits the interaction of VEGF to Flt1 & KDR receptors on the surface of endothelial cells. |
Immunological Agent; Interferon, Beta | Avonex; Rebif | Interferon beta-1α | Multiple sclerosis (relapsing forms) | IM kit:
33mcg; kit: 30mcg/0.5ml; SubQ Soln: 22mcg/0.5ml, 44mcg/0.5ml | IM, SubQ | Varies
Titrate Dosing | N/A | Purified glycoprotein which has identical amino acid sequence as natural fibroblast-derived human interferon beta |
Antipsychotic | Abilify | Aripiprazole | Autistic, bipolar, major depressive disorder, schizophrenia | ODT:
10 or 15mg;
IM Soln: 9.75mg/1.3ml; Oral Soln:
1mg/ml;
Oral Tablet:
2, 5, 10, 15, 20, 30mg;
IM Powder for Susp:
300mg/vial, 400mg/vial | Oral, IM | Varies
Bipolar max: 30mg/day
MDD max: 15mg/day | Varies
6-17YO (autistic)
6-17YO (Tourette)
10-17YO (bipolar)
13-17 (Schizo.) | Exhibits relatively high affinity for dopamine D2 & D3 receptors and serotonin 5-HT1A & 5-HT2A; (partial agonist activity at D2 and 5-HT1a and antagonist activity at 5-HT2A |
Antipsychotic; Benzisoxazole | Risperdal; Risperdal-M (ODT) | Risperidone | Autistic disorder; bipolar I disorder; schizophrenia | Oral Soln:
1mg/ml;
Oral Tablet:
0.25, 0.5, 1, 2, 3, 4mg;
ODT:
0.25, 0.5, 1, 2, 3, 4mg
IM Susp:
12.5, 25, 37.5, 50mg (Max: 50mg q2wks IM) | Oral, IM | Varies | Varies
5YO+ (Autism)
10YO+ (Bipolar)
13YO+ (Schizo.) | Selective monoaminergic antagonist with a strong affinity for 5-HT2 receptors and a slightly weaker affinity for D2 receptors |
Antipsychotic; Dibenzothiazepine | Seroquel; Seroquel XR | Quetiapine | Bipolar disorder; major depressive disorder (adjunct); manic bipolar disorder; schizophrenia | Oral Tablet:
25, 50, 100, 200, 300, 400mg;
ER Tablet:
50, 150, 200, 300, 400mg | Oral | Varies | Varies
10YO+
Max: 800mg/day | Antagonist at 5-HT1A, 5-HT2, D1, D2, H1, alpha1, and alpha2 receptors |
Antidepressant; SSRI | Celexa | Citalopram | Depression | Oral Soln: 10mg/5ml;
Oral Tablet:
10, 20, 40mg | Oral | 20mg QD (max 40mg/day) | N/A | Highly selective serotonin reuptake inhibitor (SSRI) with minimal effect of NE and DA |
Antidepressant; SSRI | Lexapro | Escitalopram | Generalized anxiety disorder; major depressive disorder | Oral Soln: 5mg/5ml; Oral Tablet: 5, 10, 20mg | Oral | Initial = 10mg/day, may increase to 20mg/day, only after a minimum of 1 week | 12YO+
10mg/day, may increase to 20mg/day only after a minimum of 3 weeks | SSRI
Enhance serotonin activity in the CNS |
Antidepressant; SSRI | Paxil;
Paxil CR | Paroxetine | Generalized anxiety disorder, major depressive disorder, OCD, panic disorder, PTSD, premenstrual dysphoric disorder, social phobia | Oral Tablet:
10, 20, 30, 40mg; ER Tablet:
12.5, 25, 37.5mg;
Oral Susp: 10mg/5ml | Oral | Varies
IR max: 60mg/day
CR max: 75mg/day | N/A | SSRI
Enhance serotonin activity in the CNS |
Antidepressant; SSRI | Prozac; Sarafem | Fluoxetine | Bulimia nervosa; bipolar I disorder (in combo w/ olanzapine); major depressive disorder; OCD; panic disorder; premenstrual dysphoric disorder | Oral Capsule:
10, 20, 40mg;
Oral Capsule (Delayed Release):
90mg;
Oral Soln/Syrup: 20mg/5ml;
Oral Tablet:
10, 20, 60mg | Oral | Varies
Max: 80mg/day | Varies
7YO+ | SSRI
Enhance serotonin activity in the CNS |